Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MoonLake Immunotherapeutics - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MLTX
Nasdaq
8731
https://moonlaketx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
- Apr 10th, 2024 11:00 am
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
- Mar 15th, 2024 3:36 pm
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
- Mar 11th, 2024 8:25 pm
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
- Mar 10th, 2024 4:00 pm
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
- Mar 4th, 2024 1:00 pm
Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)
- Mar 1st, 2024 5:38 am
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
- Feb 29th, 2024 1:00 pm
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
- Feb 26th, 2024 1:00 pm
Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics
- Feb 21st, 2024 4:44 am
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
- Jan 11th, 2024 2:55 pm
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
- Jan 10th, 2024 1:42 pm
CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics
- Dec 22nd, 2023 8:01 pm
MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses
- Nov 14th, 2023 5:13 pm
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
- Nov 14th, 2023 1:00 pm
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
- Nov 6th, 2023 9:03 pm
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
- Nov 5th, 2023 4:00 pm
12 Best Performing NASDAQ Stocks in 2023
- Oct 26th, 2023 2:33 pm
12 Best Performing Biotech Stocks in 2023
- Oct 20th, 2023 5:22 pm
MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst
- Oct 16th, 2023 8:30 pm
Why Top-Notch MoonLake Surged 11% And Almost Broke Out
- Oct 16th, 2023 8:04 pm
Scroll